These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 22413970)

  • 1. Statins and protein prenylation in cancer cell biology and therapy.
    Garcia-Ruiz C; Morales A; Fernandez-Checa JC
    Anticancer Agents Med Chem; 2012 May; 12(4):303-15. PubMed ID: 22413970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.
    Mo H; Elson CE
    Exp Biol Med (Maywood); 2004 Jul; 229(7):567-85. PubMed ID: 15229351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
    Sarrabayrouse G; Pich C; Teiti I; Tilkin-Mariame AF
    Int J Cancer; 2017 Feb; 140(4):747-755. PubMed ID: 27616679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms.
    Ahmadi Y; Ghorbanihaghjo A; Argani H
    Chem Biol Interact; 2017 Aug; 273():273-285. PubMed ID: 28668359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel prospects of statins as therapeutic agents in cancer.
    Pisanti S; Picardi P; Ciaglia E; D'Alessandro A; Bifulco M
    Pharmacol Res; 2014 Oct; 88():84-98. PubMed ID: 25009097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers.
    Mokarram P; Alizadeh J; Razban V; Barazeh M; Solomon C; Kavousipour S
    Curr Mol Pharmacol; 2017; 10(2):86-114. PubMed ID: 26758947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mevalonate Pathway and Human Cancers.
    Bathaie SZ; Ashrafi M; Azizian M; Tamanoi F
    Curr Mol Pharmacol; 2017; 10(2):77-85. PubMed ID: 26758953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
    Thurnher M; Nussbaumer O; Gruenbacher G
    Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mitochondrial unfolded protein response activator ATFS-1 protects cells from inhibition of the mevalonate pathway.
    Rauthan M; Ranji P; Aguilera Pradenas N; Pitot C; Pilon M
    Proc Natl Acad Sci U S A; 2013 Apr; 110(15):5981-6. PubMed ID: 23530189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins, Mevalonate Pathway and its Intermediate Products in Placental Development and Preeclampsia.
    Ermini L; Post M; Caniggia I
    Curr Mol Pharmacol; 2017; 10(2):152-160. PubMed ID: 26758951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins Perturb G
    Tennakoon M; Kankanamge D; Senarath K; Fasih Z; Karunarathne A
    Mol Pharmacol; 2019 Apr; 95(4):361-375. PubMed ID: 30765461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleiotropic effects of statins and related pharmacological experimental approaches.
    Alegret M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and cancer.
    Vallianou NG; Kostantinou A; Kougias M; Kazazis C
    Anticancer Agents Med Chem; 2014 Jun; 14(5):706-12. PubMed ID: 24295174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
    Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ
    Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory effects of HMG-CoA reductase inhibitors.
    Danesh FR; Anel RL; Zeng L; Lomasney J; Sahai A; Kanwar YS
    Arch Immunol Ther Exp (Warsz); 2003; 51(3):139-48. PubMed ID: 12894868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mevalonate Cascade and its Regulation in Cholesterol Metabolism in Different Tissues in Health and Disease.
    Hashemi M; Hoshyar R; Ande SR; Chen QM; Solomon C; Zuse A; Naderi M
    Curr Mol Pharmacol; 2017; 10(1):13-26. PubMed ID: 26758949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
    Yeganeh B; Wiechec E; Ande SR; Sharma P; Moghadam AR; Post M; Freed DH; Hashemi M; Shojaei S; Zeki AA; Ghavami S
    Pharmacol Ther; 2014 Jul; 143(1):87-110. PubMed ID: 24582968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways.
    Siddals KW; Marshman E; Westwood M; Gibson JM
    J Biol Chem; 2004 Sep; 279(37):38353-9. PubMed ID: 15247258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
    Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
    J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.